Header Images

About the ITOR Biorepository

A tissue bank (the foundation of the ITOR Biorepository) is critical for understanding how an individual's genetic inheritance affects the body's response to drugs - an understanding that holds the promise of safer and more effective drug treatments tailored to each individual. This is core to the Vision of the Institute for Translational Oncology Research (ITOR) of Greenville Health System (GHS):

To be an international destination center for the development and delivery of innovative, personalized cancer therapies.

From the type of mutation causing cancer to specific gene expression levels, genetic biomarkers are becoming an indispensable tool for developing new treatment models for cancer.

ITOR Biorepository Services Background

The ITOR Biorepository continues to attract leading biotechnology and pharmaceutical companies interested in developing the next generation of cancer therapies. The success of the ITOR Biorepository hinges on combining the knowledge and drug development experience of the Phase 1 Clinical Research Unit of the Greenville Health System with the scientific experience and established reputation of biotech industry partners and major research university partners such as the University of South Carolina, Clemson University and Furman University.

Rare Tumor Center:

"We're creating something in Greenville that only exists as pieces elsewhere."

GHS Cancer Institute's Medical Director, W. Larry Gluck, MD.

Patients with rare cancers and limited treament possibilities now will have significantly expanded options. The Rare Tumor Center of Greenville Health System (GHS) is the nation's first center dedicated exclusively to the treatment and research of rare cancers.

For more information: GHS Rare Tumor Center


Kiyatec is ushering a new world of cancer drug response profiling that use live cells grown and tested in a more relevant 3D tumor microenvironment. 

For more information:  Kiyatec

The Cancer Genome Atlas (TCGA):

The Cancer Genome Atlas (TCGA) is a project of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) for a comprehensive molecular interrogation of cancer.

For more information: The Cancer Genome Atlas